NAGE
Niagen Bioscience, Inc.
2.70$
+0.4%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -42.6% | -6.9% | -35.2% | -50.5% | -87.2% | -38.4% | -16.9% | -11.8% | -13.6% | -46.2% | -66.3% | -44.2% | -17.9% | -35.8% | -21.0% | 8.5% | 12.2% | 10.4% | |
| – | 8.4% | 6.8% | 5.1% | 4.9% | 3.0% | 2.7% | 1.7% | 1.8% | 1.9% | 3.4% | 2.7% | 3.3% | 2.6% | 2.4% | 2.6% | 2.0% | 1.5% | 1.1% | |
| – | 2.7% | 3.6% | 16.7% | 36.6% | 23.3% | 12.7% | 19.0% | 11.1% | 5.5% | 21.7% | 20.2% | 15.5% | 11.7% | 9.2% | 8.0% | 5.7% | 3.7% | 4.7% | |
| – | -7.7% | -1.5% | -30.1% | 3.6% | -13.0% | -7.0% | -3.3% | -12.3% | -12.8% | 9.5% | 16.4% | 0.9% | 1.8% | -7.0% | -8.3% | 5.5% | 3.1% | -6.4% | |
| – | 11.0% | 3.2% | 2.6% | 2.2% | 0.7% | 2.2% | 1.6% | 3.6% | 8.0% | 6.4% | 4.6% | 1.6% | 0.2% | 0.6% | 0.5% | 0.2% | 0.2% | 0.2% | |
| – | -11.0% | -3.1% | -2.6% | -2.2% | -0.7% | 9.8% | 10.4% | -3.6% | -8.0% | 21.7% | -5.6% | -0.5% | -0.3% | -0.6% | -0.5% | -0.2% | -0.1% | -0.2% | |
| – | -21.3% | – | – | – | -0.1% | – | – | – | – | – | -1.3% | – | – | – | – | – | 0.0% | -0.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| – | 71.9% | -1.4% | 61.0% | 30.4% | 88.7% | 45.8% | 17.6% | 24.3% | 3.5% | 230.9% | -0.3% | 36.5% | 14.6% | 53.5% | 10.6% | -0.1% | 5.4% | 5.4% | |
| – | 18.2% | -11.3% | 23.2% | -22.3% | 0.9% | 17.1% | 11.1% | 8.9% | -18.0% | 206.3% | -72.2% | -8.2% | -3.6% | 17.1% | -10.8% | 8.2% | 17.4% | 15.6% | |
| – | -53.6% | -10.0% | -37.8% | -52.7% | -87.8% | -40.7% | -18.5% | -15.4% | -21.5% | -52.6% | -70.9% | -45.8% | -18.1% | -36.4% | -21.4% | 8.3% | 12.0% | 10.2% |
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.